Flex Pharma Could Still Double From Here, Roth Analyst Says

Shares of

have lost 19 percent of value over the past year, but Joseph Pantginis of Roth Capital Partners is estimating the stock could double in value from its current valuation. Pantginis noted that following the completion of enrollment in the NLC study suing the company's proprietary formulation, the analyst is awaiting data which should inform the next NLC study with single-agent FLX-787. Pantginis also pointed out that Flex Pharma has two additional milestones in the first half of 2016, including the ex-U.S. ALS and MS studies. Bottom line, the analyst suggested that Flex Pharma's dual business model of pharmaceuticals and consumer goods offers investors "risk mitigation" and "near term revenue generating opportunity." Shares remain Buy rated with an unchanged $27 price target.